BRITISH JOURNAL OF HAEMATOLOGY
Scope & Guideline
Transforming Hematology Through Rigorous Research
Introduction
Aims and Scopes
- Clinical Trials and Treatment Efficacy:
The journal frequently publishes results from clinical trials and observational studies that assess the efficacy and safety of new treatments for haematological malignancies, including novel agents like CAR T-cell therapies, targeted therapies, and immunotherapies. - Transfusion Medicine and Blood Disorders:
Research on transfusion practices, complications, and management of blood disorders such as sickle cell disease, thalassaemia, and immune thrombocytopenia is a core focus area, addressing both clinical and logistical aspects of transfusion medicine. - Molecular and Genetic Insights:
The journal emphasizes studies that explore the molecular and genetic basis of haematological diseases, including the impact of specific mutations on prognosis and treatment response, integrating genomics with clinical outcomes. - Patient-Centered Outcomes:
There is a strong emphasis on patient-reported outcomes and quality of life assessments in patients with haematological conditions, highlighting the importance of treatment impact on patients' daily lives. - Guidelines and Best Practices:
The journal serves as a platform for disseminating guidelines and consensus statements from leading haematology societies, ensuring that practitioners have access to the latest recommendations for diagnosis and management.
Trending and Emerging
- Novel Immunotherapies and CAR T-Cell Therapies:
There is a growing body of research focused on innovative immunotherapies, particularly CAR T-cell therapies, which are being extensively studied for their efficacy in treating various haematological malignancies. - Real-World Data and Observational Studies:
An increasing number of publications emphasize the importance of real-world evidence and observational studies, providing insights into treatment effectiveness and patient outcomes in everyday clinical settings. - Genomic and Precision Medicine:
Research into genomic profiling and precision medicine is on the rise, with studies exploring how genetic mutations and biomarkers can inform tailored treatment approaches for individual patients. - Impact of COVID-19 on Haematology Patients:
The journal has seen a surge in studies assessing the impact of COVID-19 on patients with haematological conditions, including the effects on treatment protocols and patient outcomes. - Patient-Centric Research and Quality of Life Studies:
There is an emerging trend towards research that prioritizes patient perspectives, including quality of life assessments and patient-reported outcomes, recognizing the importance of holistic care in managing haematological diseases.
Declining or Waning
- Traditional Chemotherapy Approaches:
There has been a noticeable decline in publications focused solely on traditional chemotherapy regimens for haematological malignancies, as the field increasingly shifts towards targeted therapies and immunotherapies that promise improved outcomes. - Longitudinal Studies of Established Therapies:
Research on the long-term outcomes of established therapies such as older chemotherapeutic agents has decreased, likely due to the emergence of new treatment modalities that attract more research interest. - Generalized Studies Without Specific Focus:
There appears to be less emphasis on broad, generalized studies that do not target specific haematological conditions or interventions, as the field gravitates towards more precise and targeted research. - Classic Transfusion Practices:
Although transfusion medicine remains a significant area of focus, the exploration of classic transfusion practices is waning, with more attention being given to innovative transfusion strategies and technologies. - Historical Perspectives on Haematology:
Papers focusing on historical aspects of haematology or retrospective analyses of outdated treatments are becoming less common, indicating a shift towards contemporary research that addresses current challenges.
Similar Journals
LEUKEMIA
Advancing the Frontiers of Hematology and OncologyLEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.
Hematology
Unlocking Potential: Pioneering Research in Blood DisordersHematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.
Blood Cancer Discovery
Advancing the Frontiers of Hematologic ResearchBlood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.
BLOOD REVIEWS
Unveiling the latest in blood research and treatment.BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.
Hematologie
Fostering Knowledge in Blood HealthHematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.
TRANSFUSION AND APHERESIS SCIENCE
Advancing the Frontiers of Hematology and Transfusion MedicineTRANSFUSION AND APHERESIS SCIENCE, published by Pergamon-Elsevier Science Ltd, serves as a pivotal platform for researchers and practitioners in the fields of hematology, transfusion medicine, and apheresis. With an ISSN of 1473-0502 and an E-ISSN of 1878-1683, this peer-reviewed journal boasts a respectable Q3 ranking in the Hematology category as of 2023, positioning it within the 45th percentile among its counterparts. Operating from the United Kingdom, it provides comprehensive insights into the latest advancements and methodologies in transfusion practices and apheresis technology, crucial for enhancing patient care and therapeutic strategies. The journal's scope, covering key developments from 1996 to 2024, allows for a deep exploration of historical and emerging trends within the discipline. Moreover, its open access options facilitate widespread dissemination of research findings, fostering collaboration and innovation in the scientific community. For those dedicated to advancing knowledge in hematology, TRANSFUSION AND APHERESIS SCIENCE represents an essential resource, bridging theory and practice in this vital area of healthcare.
INTERNATIONAL JOURNAL OF HEMATOLOGY
Championing Excellence in Hematology ResearchThe INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.
Blood Science
Pioneering Research for Better Blood HealthBlood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.
Journal of Hematology
Empowering Research, Transforming LivesThe Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.
Egyptian Journal of Haematology
Navigating the Future of Hematology with Rigorous ResearchThe Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.